Kip Wolf is a fractional biopharma executive — a 6x founder and Navy veteran turning scientific promise into lasting value. He provides fractional and advisory leadership to ventures from formation through commercialization, delivering the organizational infrastructure, investor-ready proof points, and business development strategy that accelerate the path to the next value inflection. His original research in data integrity and AI governance gives clients something most fractional operators can't offer: a framework that treats information as a strategic asset and builds exit value into operations from day one.
Kip started working in the life sciences industry while president and CEO of GxP Data Services, a company he founded in 1997. GxP Data Services was an established leader in providing exceptional systems management, regulatory compliance, and computer system validation services to the defense contracting and life sciences industries, serving a variety of firms from start-ups to established Fortune 500 companies. Clients included Adhesives Research, GOJO Industries, Isis Pharmaceuticals, Land Studies, Lockheed Martin, Newport News Shipbuilding, PF Laboratories (Purdue Pharma), Pfizer, Roche Diagnostics, United Defense/BMI, Wyeth-Ayerst Laboratories, and Wyeth Pharmaceuticals.
Through his current consulting practice (Thaumazo Bioscience Management, Inc.), a 100% veteran-owned firm, Kip's mission is to turn early-stage biopharma programs into fundable, scalable businesses — right-sized executive leadership built for capital efficiency and value inflection. As a fractional executive and strategic advisor, he leads life science ventures from formation through commercialization — turning scientific promise into lasting value by supplying the senior operational, commercial, and quality leadership these teams need, exactly when and how they need it. He brings three decades of biopharma operations experience — from Merck to venture stage — combining deep technical expertise with financial acumen. ThaumazoBio serves ventures advancing products that improve patient outcomes, safeguard public health, and support national security priorities. Direction — Discipline — Delivery.
Kip was recently a fractional executive (CBO/COO) with Score Pharma, an early-stage start-up biopharmaceutical company developing new, more potent antibody therapeutics by transforming existing clinically proven antibody therapeutics for an improved patient response. Before this, he was an executive at X-Vax Technology, a pre-revenue pre-clinical virtual biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes, where his forecasting and operational strategy work helped enable a $56M upsized Series A.
Since 2020, Kip has actively volunteered as an advisor, mentor, and instructor for MedTechVets to bridge the gap for fellow military veterans by providing personalized career transition services, mentorship, and career development guidance. MedTechVets is a 501(c)(3) nonprofit serving military veterans during career transition and beyond, by building a professional bridge to finding and keeping meaningful employment in the Medical Technology Industry through meaningful and lasting professional relationships.
Since 2017, Kip has actively led and contributed to initiatives sponsored by organizations such as the Pathway for Patient Health, the Healthcare Products Collaborative, and Xavier Health. As a sub-team co-leader of the AI in Operations working team, he has directly contributed to advancing predictive assurance of product quality across life science business operations (e.g., manufacturing, quality, supply chain) through the power of artificial intelligence (AI) and machine learning (ML). He has been a thought leader on data integrity and information science in the life sciences industry since the late 1990s, and he co-led and co-authored the development of an industry-agnostic data integrity standard published by the American Society for Quality as "ASQ TR3:2022 Data Integrity: Guidelines for collecting, recording and retaining data within the scope of quality management systems" with the potential to be applied as an ANSI Standard.
Kip is an incoming PhD student in Information Science at Drexel University (fall 2026), with formal graduate studies in Drug Development at Temple University, and an undergraduate degree in Management of Information Systems and an MBA from Eastern University.
